[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100451632":3},{"organization":4,"armGroups":7,"interventions":12,"overallOfficials":17,"centralContacts":18,"locations":28,"responsibleParty":84,"collaborators":17,"id":86,"slug":17,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":87,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":17,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":108,"whyStopped":17,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"University Hospital, Caen","OTHER",[8],{"label":9,"type":6,"description":9,"interventionNames":10},"Patients with AML",[11],"Other: Bone osteodensitometry",[13],{"type":6,"name":14,"description":15,"armGroupLabels":16,"otherNames":17},"Bone osteodensitometry","Evaluation of bone osteodensitometry",[9],null,[19,24],{"name":20,"role":21,"phone":22,"phoneExt":17,"email":23},"Agathe FARGE, PhD","CONTACT","+33 2.31.27.21.40","farge-a@chu-caen.fr",{"name":25,"role":21,"phone":26,"phoneExt":17,"email":27},"DRCI secretary","+33.2.31.06.57.81","drci-sec@chu-caen.fr",[29,45,56,70],{"facility":30,"status":17,"city":31,"state":17,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Chu Amiens","Amiens","80054","France",{"type":35,"coordinates":36},"Point",[37,38],2.3,49.9,{"lat":38,"lon":37},[41],{"name":42,"role":21,"phone":43,"phoneExt":17,"email":44},"MAROLLEAU Jean-Pierre, MD\u002FPhD","+33 3.22.45.59.20","marolleau.jean-pierre@chu-amiens.fr",{"facility":46,"status":17,"city":47,"state":17,"zip":48,"country":33,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"CHU CAEN","Caen","14033",{"type":35,"coordinates":50},[51,52],-0.35912,49.18585,{"lat":52,"lon":51},[55],{"name":20,"role":21,"phone":22,"phoneExt":17,"email":23},{"facility":57,"status":17,"city":58,"state":17,"zip":59,"country":33,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Chu Lille","Lille","59000",{"type":35,"coordinates":61},[62,63],3.05512,50.63391,{"lat":63,"lon":62},[66],{"name":67,"role":21,"phone":68,"phoneExt":17,"email":69},"Isabelle LEGROUX, PhD","+33 3.20.44.59.62","Isabelle.legroux@chru-lille.fr",{"facility":71,"status":17,"city":72,"state":17,"zip":73,"country":33,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Chu Rouen","Rouen","76038",{"type":35,"coordinates":75},[76,77],1.09932,49.44313,{"lat":77,"lon":76},[80],{"name":81,"role":21,"phone":82,"phoneExt":17,"email":83},"Fabrice JARDIN, MD\u002FPhD","+33 2.32.08.24.51","fabrice.jardin@rouen.fnclcc.fr",{"type":85,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100451632",false,"NCT05161026","Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry","Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry Coupled With FRAX \u002F TBS in Allo-HSCT","REMODALLO","Inclusion Criteria:\n\n* Cytological diagnosis of acute myeloid leukemia (AML) with indication for a first-line allo-HSCTs transplant\n* Patient affiliated to the social security system\n* For women of childbearing age, use of reliable contraception throughout the study in accordance with the CPR of the drugs used.\n* The patient must be able to comply with study visits and per protocol procedures\n* Patient who has been informed of the study and has signed his informed consent\n\nExclusion Criteria:\n\n* Person under guardianship or curatorship, or unable to understand the purpose of the study.\n* Hematologic malignancies other than AML\n* History of neoplasia with bone involvement (sarcoma, multiple myeloma, metastasis...) and\u002For any solid cancer less than 5 years old\n* History of fracture of the femoral neck prior to the diagnosis of hematologic malignancies\n* Known bone involvement related to AML at diagnosis\n* Primary or secondary osteoporosis known to the diagnosis of hematologic malignancies\n* Corticotherapy \\> 3 months at a dose \\> 7.5mg\u002Fday prior to the diagnosis of hematological disease\n* Autograft or anterior allograft\n* Pathologies influencing bone metabolism: known inflammatory rheumatism (rheumatoid arthritis, ...), primary hyperparathyroidism, chronic renal failure (GFR \\\u003C or = at 30ml \u002F min \u002F 1.73m2)\n* Pregnant or lactating woman","ALL","18 Years","75 Years",{"count":97,"type":98},120,"ESTIMATED","INTERVENTIONAL",[101],"NA","Evaluation of variation of mineral density and bone microarchitecture after allogeneic HSCTs transplant in hematologic malignancies. Comparison with the general population.",[104],"Myeloid Leukemia, Acute",[106,107],"allo-HSCTs transplant","osteoporosis","NOT_YET_RECRUITING","2021-12-06",{"date":111,"type":112},"2021-12-16","ACTUAL",{"date":114,"type":98},"2021-12-10",{"date":116,"type":98},"2027-12-01",{"name":5,"class":6},4]